Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

autoimmune diseases

Oct 04, 2024

Which Key Player Holds the Potential to Corner the Rheumatoid Arthritis Therapeutics Market?

Jan 02, 2024

Cytokinetics Announces Results From SEQUOIA-HCM Clinical Trial of Aficamten; FDA Approves Chiesi’s FILSUVEZ Topical Gel; Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform; AstraZeneca to Acquire Gracell; Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application; Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362)

Dec 28, 2023

Savara Introduced aPAP ClearPathTM; RaySearch Released RayStation 2024A; FDA Approved Expanded Label for CVRx Neuromod Tech; FDA Clearance to Masimo’s Baby Monitoring System; Kansas City Proton Institute’s Advanced MEVION S250i Proton Therapy System; Gore’s Arise II Pivotal Study of the Gore® Ascending Stent Graft

Oct 11, 2023

Harnessing the Power of Immunomodulators: Applications and Implications

Jul 17, 2023

Analyzing Strategies in Polymyositis and Dermatomyositis Treatment 

May 29, 2023

ANCA-associated Vasculitis Treatment Market: Unraveling the Complexities

Aug 09, 2022

FDA Approves AstraZeneca’s Enhertu; Bayer Wins FDA Approval for Prostate Cancer Therapy, Nubeqa; Gilead Sciences to Acquire MiroBio; AstraZeneca & Merck’s Lynparza Gets EU Approval; Pfizer to Acquire Global Blood Therapeutics; Sironax Raises USD 200 Million

Mar 29, 2022

Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval

Jan 28, 2022

Evaluating the Upcoming Drugs in Pipeline for Major Autoimmune Diseases

Jul 21, 2021

Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies

Newsletter/Whitepaper